ATE458000T1 - Zielgerichtete fusionsproteine für die krebstherapie - Google Patents

Zielgerichtete fusionsproteine für die krebstherapie

Info

Publication number
ATE458000T1
ATE458000T1 AT06821700T AT06821700T ATE458000T1 AT E458000 T1 ATE458000 T1 AT E458000T1 AT 06821700 T AT06821700 T AT 06821700T AT 06821700 T AT06821700 T AT 06821700T AT E458000 T1 ATE458000 T1 AT E458000T1
Authority
AT
Austria
Prior art keywords
moiety
cancer
apoptosis
fusion proteins
cell
Prior art date
Application number
AT06821700T
Other languages
English (en)
Inventor
Kapil Maithal
Dhatchana Nachiappan
Rama Mukherjee
Original Assignee
Dabur Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Pharma Ltd filed Critical Dabur Pharma Ltd
Application granted granted Critical
Publication of ATE458000T1 publication Critical patent/ATE458000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06821700T 2005-11-18 2006-11-16 Zielgerichtete fusionsproteine für die krebstherapie ATE458000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3084DE2005 2005-11-18
PCT/IN2006/000452 WO2007057922A1 (en) 2005-11-18 2006-11-16 Targeted fusion proteins for cancer therapy

Publications (1)

Publication Number Publication Date
ATE458000T1 true ATE458000T1 (de) 2010-03-15

Family

ID=37772861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06821700T ATE458000T1 (de) 2005-11-18 2006-11-16 Zielgerichtete fusionsproteine für die krebstherapie

Country Status (7)

Country Link
US (1) US20100184651A1 (de)
EP (1) EP1957524B1 (de)
AT (1) ATE458000T1 (de)
AU (1) AU2006314037B2 (de)
CA (1) CA2630012A1 (de)
DE (1) DE602006012358D1 (de)
WO (1) WO2007057922A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
DE102007042107B4 (de) * 2007-09-05 2010-07-15 Siemens Ag Pharmazeutische Zusammensetzung mit eisenbindendem Agens
WO2009139570A1 (en) * 2008-05-14 2009-11-19 Kyungpook National University Industry-Academic Cooperation Foundation Peptides for targeting apoptotic cells and uses thereof
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
CA2730078A1 (en) * 2008-07-08 2010-01-14 Daiichi Sankyo Company, Limited Nitrogen-containing aromatic heterocyclyl compound
RU2589255C2 (ru) * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Модифицированные вазоактивные интестинальные пептиды
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2015134833A2 (en) * 2014-03-07 2015-09-11 Proda Biotech Llc Therapeutic proteins for treating cancers and methods for using such proteins
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
CN107427556B (zh) 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
AU2016358296B2 (en) 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803358B1 (en) * 2000-04-14 2004-10-12 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
CA2288943C (en) * 1997-04-30 2011-02-01 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
US20040171809A1 (en) * 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
EP1861419B1 (de) * 2005-03-15 2011-06-29 Allergan, Inc. Modifizierte clostridientoxine mit erhöhter targeting-kapazität für endogene clostridientoxin-rezeptorsysteme

Also Published As

Publication number Publication date
EP1957524B1 (de) 2010-02-17
DE602006012358D1 (de) 2010-04-01
WO2007057922A1 (en) 2007-05-24
EP1957524A1 (de) 2008-08-20
US20100184651A1 (en) 2010-07-22
AU2006314037B2 (en) 2010-09-23
AU2006314037A1 (en) 2007-05-24
CA2630012A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE458000T1 (de) Zielgerichtete fusionsproteine für die krebstherapie
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
RU2020106752A (ru) Субстраты матриксной металлопротеиназы и другие расщепляемые фрагменты и способы их использования
MX348047B (es) Proteinas de fusion terapeuticas.
AR060862A1 (es) Proteinas de fusion rage, formulaciones y metodos de uso de estas
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
MX2009013372A (es) Proteinas de fusion bifuncionales de la hormona estimulante de alfa-melanocitos (alfa-msh) y proteina natriuretica atrial (anp) y usos en hipertension y lesion de riñon aguda.
HK1125387A1 (en) Compositions and methods for fusion protein separation
CY1122794T1 (el) Συνθεσεις αλφα-γαλακτοσιδασης
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CL2008001661A1 (es) Proteina de fusion que comprende un peptido natriuretico y un dominio fc de un anticuerpo; molecula de acido nucleico que la codifica; composicion farmaceutica que la comprende; y su uso para tratar enfermedades asociadas con la actividad diuretica, natriuretica y vasodilatadora anomala.
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
MY192113A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
MX2009003126A (es) Agente para prevenir/tratar el cancer.
GT200700059A (es) Proteinas de fusion de exendina
RU2013110876A (ru) Активируемые биспецифические антитела
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
AR119080A1 (es) Proteínas multiespecíficas
PE20081546A1 (es) Antagonistas del dr6
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
ECSP088999A (es) Sintesis de un peptido insulinotropico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties